Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
Upadacitinib was more effective than tofacitinib in inducing remission in ulcerative colitis patients. The incidence of adverse events was significantly higher with upadacitinib than tofacitinib.
Authors
- K Takenaka (ORCID: https://orcid.org/0000-0002-7861-8383)
- Shuji Hibiya (ORCID: https://orcid.org/0000-0001-8823-7755)
- Ami Kawamoto (ORCID: https://orcid.org/0000-0002-8549-4999)
- Toshimitsu Fujii (ORCID: https://orcid.org/0000-0003-3048-7270)
- Ryo Morikawa
- Hiromichi Shimizu (ORCID: https://orcid.org/0000-0003-3268-0613)
- Masakazu Nagahori (ORCID: https://orcid.org/0000-0002-5323-7058)
- Kazuo Ohtsuka (ORCID: https://orcid.org/0000-0002-2409-9709)
- Ryuichi Okamoto (ORCID: https://orcid.org/0000-0002-7047-571X)
- Akiko Tamura
Publication Details
- Journal
- Intestinal Research
- Published
- 2025-03-20
- DOI
- https://doi.org/10.5217/ir.2024.00187
- Citations
- 8
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 14.54